NPScreen develops a Nasopharyngeal cancer screening test that is simple, non-invasive, and 99% accurate
MARKHAM, ON, March 20, 2014 /PRNewswire/ – A Markham, Ontario-based company has
developed a specialized test which screens for nasopharyngeal cancer.
Nasopharyngeal cancer, known as NPC, is a rare but deadly disease. It is
global in scope, and individuals with a Hong Kong, Southeast Asian,
Inuit, North African, or Middle Eastern background have a higher risk
for NPC. These individuals may benefit from this early screening test.
In the early stages, NPC has few obvious symptoms, and the cancer often
grows undetected, hidden in the nasopharynx, near the center of the
head. Usually it is diagnosed after the tumor is well developed, making
treatment difficult with poor survival outcomes. When detected early
and treated, the chances of full recovery are almost 90%.
NPScreen has developed a genetic test that detects the cancer in its
early stages, when it is still curable. The test is quick,
non-invasive, and most importantly, 99% accurate.
“We are excited about the launch of this innovative, unique screening
process that we believe will dramatically change the course of
Nasopharyngeal cancer and save thousands of lives EVERY year.” says
NPScreen President Dr. John Phillips.
The screening process is managed as a simple, non-invasive office
procedure. Using a uniquely designed instrument to brush the back of
the patient’s throat, the specialist takes a sample of surface cells,
which are then analyzed for the presence of the Epstein-Barr viral
genome sequence. The Epstein-Barr virus infects the epithelial cells of
the nasopharynx and is closely linked to the development of NPC.
There are numerous clinics in Canada, the U.S.A., Hong Kong and
Singapore, where specialists are now using the NPScreen test to screen
patients and their families for this aggressive cancer.
NPScreen (www.npscreen.com) is a Canadian biotech company that has developed an innovative genetic
test for a deadly cancer. The test detects nasopharyngeal cancer in the
early stages, allowing quicker treatment and better chances for
survival. The company’s management structure is supported by academic
and clinical partnerships across North America and Asia, including a
team consisting of the world’s leading experts in the fields of
diagnosing and treating nasopharyngeal cancer.